1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Generics in Scandinavia

Generics in Scandinavia

  • January 2016
  • -
  • MarketLine
  • -
  • 32 pages

Introduction

Generics in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Scandinavia generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

- For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

- The Scandinavian generics market is expected to generate total revenues of $2.8bn in 2015, representing a compound annual growth rate (CAGR) of 6.8% between 2011 and 2015.

- Market consumption volume is forecast to reach a total of 49.9% of total pharma volume in 2015.

- Denmark has some of the lowest prices on generics in Europe; they are around 86% lower than Norwegian prices and 12% lower than Swedish prices. Generic drugs represent a saving of DKK1bn compared to Norway and DKK750m compared to Sweden.

Features

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Scandinavia

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Scandinavia

- Leading company profiles reveal details of key generics market players’ global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the Scandinavia generics market with five year forecasts by both value and volume

- Macroeconomic indicators provide insight into general trends within the Scandinavia economy

Key Questions Answered

- What was the size of the Scandinavia generics market by value in 2015?

- What will be the size of the Scandinavia generics market in 2020?

- What factors are affecting the strength of competition in the Scandinavia generics market?

- How has the market performed over the last five years?

- How large is Scandinavia’s generics market in relation to its regional counterparts?

Table Of Contents

Generics in Scandinavia
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market volume 9
Market Segmentation 10
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Market volume forecast 12
Five Forces Analysis 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
Mylan Inc. 19
Sandoz International GmbH 22
Sanofi SA 23
Teva Pharmaceutical Industries Limited 26
Methodology 29
Industry associations 30
Related MarketLine research 30
Appendix 31
About MarketLine 31

List of Tables
Table 1: Scandinavia generics market value: $ billion, 2011-15(e)
Table 2: Scandinavia generics market volume: % of total pharma volume, 2011-15(e)
Table 3: Scandinavia generics market geography segmentation: $ billion, 2015(e)
Table 4: Scandinavia generics market value forecast: $ billion, 2015-20
Table 5: Scandinavia generics market volume forecast: % of total pharma volume, 2015-20
Table 6: Mylan Inc.: key facts
Table 7: Mylan Inc.: key financials ($)
Table 8: Mylan Inc.: key financial ratios
Table 9: Sandoz International GmbH: key facts
Table 10: Sanofi SA: key facts
Table 11: Sanofi SA: key financials ($)
Table 12: Sanofi SA: key financials (€)
Table 13: Sanofi SA: key financial ratios
Table 14: Teva Pharmaceutical Industries Limited: key facts
Table 15: Teva Pharmaceutical Industries Limited: key financials ($)
Table 16: Teva Pharmaceutical Industries Limited: key financial ratios

List of Figures
Figure 1: Scandinavia generics market value: $ billion, 2011-15(e)
Figure 2: Scandinavia generics market volume: % of total pharma volume, 2011-15(e)
Figure 3: Scandinavia generics market geography segmentation: % share, by value, 2015(e)
Figure 4: Scandinavia generics market value forecast: $ billion, 2015-20
Figure 5: Scandinavia generics market volume forecast: % of total pharma volume, 2015-20
Figure 6: Forces driving competition in the generics market in Scandinavia, 2015
Figure 7: Drivers of buyer power in the generics market in Scandinavia, 2015
Figure 8: Drivers of supplier power in the generics market in Scandinavia, 2015
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Scandinavia, 2015
Figure 10: Factors influencing the threat of substitutes in the generics market in Scandinavia, 2015
Figure 11: Drivers of degree of rivalry in the generics market in Scandinavia, 2015
Figure 12: Mylan Inc.: revenues and profitability
Figure 13: Mylan Inc.: assets and liabilities
Figure 14: Sanofi SA: revenues and profitability
Figure 15: Sanofi SA: assets and liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues and profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets and liabilities

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.